Comparative Pharmacology
Head-to-head clinical analysis: DOLENE AP 65 versus INVAGESIC FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE AP 65 versus INVAGESIC FORTE.
DOLENE AP-65 vs INVAGESIC FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLENE AP-65 is a combination of dipyrone (metamizole) and propantheline. Dipyrone is a non-opioid analgesic and antipyretic that acts centrally and peripherally via inhibition of cyclooxygenase and activation of the endocannabinoid system. Propantheline is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and spasm.
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
DOLENE AP-65 (propoxyphene napsylate 100 mg and acetaminophen 650 mg). Adult: 1 tablet orally every 4 hours as needed for pain. Maximum: 6 tablets per day.
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
2-3 hours in adults with normal hepatic function; prolonged in hepatic impairment (up to 5-10 hours) and in neonates (up to 3-5 hours)
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in CrCl <30 mL/min)
Renal: 90% (50% as acetaminophen glucuronide, 30% as sulfate, 5% as cysteine, 3% as unchanged drug, 2% as other metabolites); Fecal: <5%
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination